KENNETH HAWKINS: Open Payments
NPI 1730692914 · SENATOBIA, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 32 payments from 12 companies in 2025. Trend: 2023 $2,272 · 2024 $4,943 · 2025 $693
Food & beverage: $693
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $169 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $167 |
| Teva Pharmaceuticals USA, Inc. | 2 | $129 |
| Novo Nordisk Inc | 3 | $49 |
| PFIZER INC. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: JARDIANCE, UBRELVY, AUSTEDO XR, Ozempic, QULIPTA, NURTEC ODT, FARXIGA, TRELEGY ELLIPTA.
Industry payments across MS — which companies pay providers there.
